Phase I study of camrelizumab in patients with advanced solid tumors

Signal Transduct Target Ther. 2023 Feb 1;8(1):47. doi: 10.1038/s41392-022-01213-6.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • camrelizumab

Associated data

  • ClinicalTrials.gov/NCT02721589